Synapse - Vicky Makker

Results (265)

Randomized phase 3 study of lenvatinib plus pembrolizumab for advanced endometrial cancer (aEC): Subgroup analysis of patients with DNA mismatch repair deficient (DMMR) tumors

Meeting Abstract

Makker, V.; Colombo, N.; Casado Herráez, A.; Santin, A.; Colomba, E.; Miller, D.; Fujiwara, K.; Pignata, S.; Banerjee, S.; Monk, B.; more...
International Journal of Gynecological Cancer (2021)

Fulltext@MSK | Save

A multicenter, open-label, randomized, phase 3 study to compare the efficacy and safety of lenvatinib in combination with pembrolizumab vs treatment of physician's choice in patients with advanced endometrial cancer: Study 309/Keynote-775

Meeting Abstract

Makker, V.; Colombo, N.; Casado Herráez, A.; Santin, A.; Colomba, E.; Miller, D.; Fujiwara, K.; Pignata, S.; Baron-Hay, S.; Ray-Coquard, I.; more...
International Journal of Gynecological Cancer (2021)

Fulltext@MSK | Save

Endometrial cancer

Review

Makker, V.; MacKay, H.; Ray-Coquard, I.; Levine, D. A.; Westin, S. N.; Aoki, D.; Oaknin, A.
Nature Reviews Disease Primers (2021)

Fulltext@MSK | Save

SIENDO/ENGOT-EN5/GOG-3055: A randomized phase 3 trial of maintenance selinexor versus placebo after combination platinum-based chemotherapy in advanced or recurrent endometrial cancer

Meeting Abstract

Vergote, I.; Perez-Fidalgo, J. A.; Hamilton, E. P.; Van Gorp, T.; Valabrega, G.; Laenen, A.; Oza, A. M.; Levy, T.; Cibula, D.; Sehouli, J.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Health-related quality of life (HRQoL) in advanced endometrial cancer (aEC) patients (pts) treated with lenvatinib plus pembrolizumab or treatment of physician's choice (TPC)

Meeting Abstract

Lorusso, D.; Colombo, N.; Herraez, A. C.; Santin, A.; Colomba, E.; Miller, D. S.; Fujiwara, K.; Pignata, S.; Baron-Hay, S. E.; Ray-Coquard, I. L.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

LIO-1: Lucitanib + nivolumab in patients with advanced solid tumors - Updated phase 1b results and initial experience in phase 2 ovarian cancer cohort

Meeting Abstract

Hamilton, E. P.; Jackson, C. C.; Eskander, R. N.; Backes, F. J.; Makker, V.; Musa, F.; Olawaiye, A.; Alldredge, J.; Pothuri, B.; Secord, A. A.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Outcomes by histology and prior therapy with lenvatinib plus pembrolizumab vs treatment of physician's choice in patients with advanced endometrial cancer (Study 309/KEYNOTE-775)

Meeting Abstract

Colombo, N.; Lorusso, D.; Casado Herráez, A.; Santin, A. D.; Colomba, E.; Miller, D. S.; Fujiwara, K.; Pignata, S.; Floquet, A.; Monk, B. J.; more...
Annals of Oncology (2021)

Fulltext@MSK | Save

Association between biomarkers and clinical outcomes of lenvatinib (L) + pembrolizumab (P) in advanced endometrial cancer (EC): Results from KEYNOTE-146/study 111

Meeting Abstract

Makker, V.; Taylor, M. H.; Aghajanian, C.; Cohn, A. L.; Brose, M. S.; DiSimone, C.; Cao, A.; Suttner, L.; Loboda, A.; Cristescu, R.; more...
Annals of Oncology (2021)

Fulltext@MSK | Save

Secondary cytoreduction and carboplatin hyperthermic intraperitoneal chemotherapy for platinum-sensitive recurrent ovarian cancer: An MSK Team Ovary phase II study

Journal Article

Zivanovic, O.; Chi, D. S.; Zhou, Q.; Iasonos, A.; Konner, J. A.; Makker, V.; Grisham, R. N.; Brown, A. K.; Nerenstone, S.; Diaz, J. P.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Characterization and management of adverse reactions in patients with advanced endometrial carcinoma treated with lenvatinib plus pembrolizumab

Journal Article

Makker, V.; Taylor, M. H.; Oaknin, A.; Casado Herraez, A.; Orlowski, R.; Dutta, L.; Ren, M.; Zale, M.; O'Malley, D. M.
The Oncologist (2021)

Fulltext@MSK | Save